Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses.
Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Umviligihozo G, Kalikawe R, Speckmaier S, Moran-Garcia N, Datwani S, Duncan MC, Agafitei O, Ennis S, Young L, Ali H, Ganase B, Omondi FH, Dong W, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis AH, Leung V, Holmes DT, DeMarco ML, Simons J, Hedgcock M, Prystajecky N, Lowe CF, Pantophlet R, Romney MG, Barrios R, Guillemi S, Brumme CJ, Montaner JSG, Hull M, Harris M, Niikura M, Brockman MA, Brumme ZL. Lapointe HR, et al. Among authors: hedgcock m. J Infect Dis. 2023 Apr 12;227(7):838-849. doi: 10.1093/infdis/jiac229. J Infect Dis. 2023. PMID: 35668700 Free PMC article.
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy.
Brumme ZL, Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Duncan MC, Yaseen F, Agafitei O, Ennis S, Ng K, Basra S, Lim LY, Kalikawe R, Speckmaier S, Moran-Garcia N, Young L, Ali H, Ganase B, Umviligihozo G, Omondi FH, Atkinson K, Sudderuddin H, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis AH, Leung V, Holmes D, DeMarco ML, Simons J, Hedgcock M, Romney MG, Barrios R, Guillemi S, Brumme CJ, Pantophlet R, Montaner JSG, Niikura M, Harris M, Hull M, Brockman MA. Brumme ZL, et al. Among authors: hedgcock m. NPJ Vaccines. 2022 Feb 28;7(1):28. doi: 10.1038/s41541-022-00452-6. NPJ Vaccines. 2022. PMID: 35228535 Free PMC article.
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy.
Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Speckmaier S, Barad E, Moran-Garcia N, Datwani S, Duncan MC, Kalikawe R, Ennis S, Young L, Ganase B, Omondi FH, Umviligihozo G, Dong W, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis AH, Leung V, Holmes D, DeMarco ML, Simons J, Hedgcock M, Prystajecky N, Lowe CF, Romney MG, Barrios R, Guillemi S, Brumme CJ, Montaner JSG, Hull M, Harris M, Niikura M, Brockman MA, Brumme ZL. Lapointe HR, et al. Among authors: hedgcock m. AIDS. 2023 Apr 1;37(5):709-721. doi: 10.1097/QAD.0000000000003469. Epub 2022 Dec 22. AIDS. 2023. PMID: 36545783 Free PMC article.
Lymphogranuloma venereum.
Eckbo EJ, Hedgcock M, Grennan T. Eckbo EJ, et al. Among authors: hedgcock m. CMAJ. 2021 Dec 13;193(49):E1889. doi: 10.1503/cmaj.210853. CMAJ. 2021. PMID: 34903592 Free PMC article. No abstract available.
[No title available]
[No authors listed] [No authors listed] PMID: 35165140
Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex Human Immunodeficiency Virus Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1).
Mounzer K, Slim J, Ramgopal M, Hedgcock M, Bloch M, Santana J, Mendes I, Guo Y, Arora P, Montezuma-Rusca JM, Sklar P, Baeten JM, Segal-Maurer S. Mounzer K, et al. Among authors: hedgcock m. Clin Infect Dis. 2024 Nov 26:ciae522. doi: 10.1093/cid/ciae522. Online ahead of print. Clin Infect Dis. 2024. PMID: 39589133
T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy.
Datwani S, Kalikawe R, Waterworth R, Mwimanzi FM, Liang R, Sang Y, Lapointe HR, Cheung PK, Omondi FH, Duncan MC, Barad E, Speckmaier S, Moran-Garcia N, DeMarco ML, Hedgcock M, Costiniuk CT, Hull M, Harris M, Romney MG, Montaner JSG, Brumme ZL, Brockman MA. Datwani S, et al. Among authors: hedgcock m. Viruses. 2024 Apr 24;16(5):661. doi: 10.3390/v16050661. Viruses. 2024. PMID: 38793543 Free PMC article.
People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses.
Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Umviligihozo G, Kalikawe R, Speckmaier S, Moran-Garcia N, Datwani S, Duncan MC, Agafitei O, Ennis S, Young L, Ali H, Ganase B, Omondi FH, Dong W, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis AH, Leung V, Holmes D, DeMarco ML, Simons J, Hedgcock M, Prystajecky N, Lowe CF, Pantophlet R, Romney MG, Barrios R, Guillemi S, Brumme CJ, Montaner JSG, Hull M, Harris M, Niikura M, Brockman MA, Brumme ZL. Lapointe HR, et al. Among authors: hedgcock m. medRxiv [Preprint]. 2022 Mar 23:2022.03.22.22272793. doi: 10.1101/2022.03.22.22272793. medRxiv. 2022. Update in: J Infect Dis. 2023 Apr 12;227(7):838-849. doi: 10.1093/infdis/jiac229 PMID: 35350205 Free PMC article. Updated. Preprint.
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy.
Brumme ZL, Mwimanzi F, Lapointe HR, Cheung P, Sang Y, Duncan MC, Yaseen F, Agafitei O, Ennis S, Ng K, Basra S, Lim LY, Kalikawe R, Speckmaier S, Moran-Garcia N, Young L, Ali H, Ganase B, Umviligihozo G, Omondi FH, Atkinson K, Sudderuddin H, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis AH, Leung V, Holmes D, DeMarco ML, Simons J, Hedgcock M, Romney MG, Barrios R, Guillemi S, Brumme CJ, Pantophlet R, Montaner JSG, Niikura M, Harris M, Hull M, Brockman MA. Brumme ZL, et al. Among authors: hedgcock m. medRxiv [Preprint]. 2021 Oct 15:2021.10.03.21264320. doi: 10.1101/2021.10.03.21264320. medRxiv. 2021. Update in: NPJ Vaccines. 2022 Feb 28;7(1):28. doi: 10.1038/s41541-022-00452-6 PMID: 34671779 Free PMC article. Updated. Preprint.
Double-blind study of the safety, tolerance, and diagnostic efficacy of iopromide as compared with iopamidol and iohexol in patients requiring aortography and visceral angiography.
Faykus MH Jr, Cope C, Athanasoulis C, Druy EM, Hedgcock M, Miller FJ, Bron K. Faykus MH Jr, et al. Among authors: hedgcock m. Invest Radiol. 1994 May;29 Suppl 1:S98-101; discussion S106. doi: 10.1097/00004424-199405001-00019. Invest Radiol. 1994. PMID: 8071053 Clinical Trial.
51 results